Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

被引：22

作者：

Gay, Francesca ^{[1
]}

Cerrato, Chiara ^{[1
]}

Scalabrini, Delia Rota ^{[1
]}

Galli, Monica ^{[1
]}

Belotti, Angelo ^{[1
]}

Zamagni, Elena ^{[1
]}

Ledda, Antonio ^{[1
]}

Grasso, Mariella ^{[1
]}

Angelucci, Emanuele ^{[1
]}

Liberati, Anna Marina ^{[1
]}

Tosi, Patrizia ^{[1
]}

Pisani, Francesco ^{[1
]}

Spada, Stefano ^{[1
]}

Annibali, Ombretta ^{[1
]}

Baraldi, Anna ^{[1
]}

Omede, Paola ^{[1
]}

Galieni, Piero ^{[1
]}

Rizzi, Rita ^{[1
]}

Pescosta, Norbert ^{[1
]}

Ronconi, Sonia ^{[1
]}

Vincelli, Donatella ^{[1
]}

Cafro, Anna Maria ^{[1
]}

Offidani, Massimo ^{[1
]}

Palumbo, Antonio ^{[2
,3
]}

Musto, Pellegrino ^{[1
]}

Cavo, Michele ^{[1
]}

Boccadoro, Mario ^{[1
]}

机构：

[1] European Myeloma Network, GIMEMA, Milan, Italy

[2] Univ Torino, Turin, Italy

[3] Takeda Pharmaceut Co, Zurich, Switzerland

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

121

引用

页数：4

共 50 条

[31] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara) [J].

Bhutani, Manisha ;

Robinson, Myra ;

Atrash, Shebli ;

Watts, Nicole ;

Paul, Barry ;

Chhabra, Saurabh ;

Korde, Neha ;

Begic, Xhevahire ;

Foureau, David M. ;

Chung, David J. ;

Pineda-Roman, Mauricio ;

Koya, Brinda ;

Varga, Cindy ;

Ai, Jing ;

Daniels, Natonya ;

Norek, Sarah ;

Sutton, Sara A. ;

Anderson, Michelle B. ;

Jewell, Ashley N. ;

Eldridge, Paul W. ;

Acampora, Donna ;

Symanowski, James T. ;

Costa, Luciano J. ;

Usmani, Saad ;

Voorhees, Peter M. .

BLOOD, 2022, 140 :4393-4395

[32] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM) [J].

Costa, Luciano ;

Chhabra, Saurabh ;

Medvedova, Eva ;

Dholaria, Bhagirathbhai ;

Schmidt, Timothy ;

Silbermann, Rebecca ;

Godby, Kelly ;

Dhakal, Binod ;

Bal, Susan ;

Giri, Smith ;

D'Souza, Anita ;

Cornell, Robert ;

Hardwick, Pamela ;

Omel, James ;

Hari, Parameswaran ;

Callander, Natalie S. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 :S33-S33

[33] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study [J].

Knop, Stefan ;

Stuebig, Thomas ;

Kull, Miriam ;

Greil, Richard ;

Steiner, Normann ;

Bassermann, Florian ;

Nogai, Axel ;

von Lilienfeld-Toal, Marie ;

Janjetovic, Snjezana ;

Trautmann-Grill, Karolin ;

Bittrich, Max ;

Engelhardt, Monika Martha ;

Hoferer, Anette ;

Theurich, Sebastian ;

Binder, Mascha ;

Zojer, Niklas ;

Duerk, Heinz A. ;

Brueggemann, Monika ;

Held, Swantje ;

Einsele, Hermann .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[34] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial [J].

Jacobus, Susanna J. ;

Cohen, Adam D. ;

Weiss, Matthias ;

Callander, Natalie Scott ;

Singh, Avina A. ;

Parker, Terri L. ;

Menter, Alex R. ;

Yang, Xuezhong ;

Parsons, Benjamin Marshall ;

Kumar, Pankaj ;

Kapoor, Prashant ;

Rosenberg, Aaron Seth ;

Zonder, Jeffrey A. ;

Faber, Edward Anthony ;

Lonial, Sagar ;

Richardson, Paul G. ;

Orlowski, Robert Z. ;

Wagner, Lynne I. ;

Rajkumar, S. Vincent .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)

[35] Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT) [J].

Derman, Benjamin A. ;

Cooperrider, Jennifer H. ;

Rosenblatt, Jacalyn ;

Avigan, David ;

Rampurwala, Murtuza M. ;

Major, Ajay ;

Karrison, Theodore ;

Jiang, Ken ;

Kubicki, Tadeusz ;

Jakubowiak, Andrzej J. .

BLOOD, 2023, 142

[36] Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) [J].

Bhutani, Manisha ;

Robinson, Myra ;

Atrash, Shebli ;

Paul, Barry ;

Pineda-Roman, Mauricio ;

Foureau, David ;

Varga, Cindy ;

Friend, Reed ;

Begic, Xhevahire ;

Norek, Sarah ;

Drennan, Tiffany ;

Anderson, Michelle B. ;

Symanowski, James ;

Voorhees, Peter M. ;

Usmani, Saad Z. .

BLOOD, 2023, 142

[37] Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial [J].

Wester, Ruth ;

Zweegman, Sonja ;

van der Holt, Bronno ;

Kersten, Marie Jose ;

Vellenga, Edo ;

van Marwijk-Kooy, Marinus ;

Asselbergs, Emelie ;

de Weerdt, Okke ;

Minnema, Monique C. ;

Lonergan, Sarah ;

Palumbo, Antonio ;

Broijl, Annemiek ;

Sonneveld, Pieter .

HEMASPHERE, 2020, 4 (04)

[38] Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM) [J].

Kubicki, Tadeusz ;

Dytfeld, Dominik ;

Wrobel, Tomasz ;

Jamroziak, Krzysztof ;

Robak, Pawel ;

Czyz, Jaroslaw ;

Tyczynska, Agata ;

Druzd-Sitek, Agnieszka ;

Giannopoulos, Krzysztof ;

Nowicki, Adam ;

Szczepaniak, Tomasz ;

Lojko-Dankowska, Anna ;

Matuszak, Magdalena ;

Gil, Lidia ;

Pula, Bartosz Michal ;

Rybka, Justyna ;

Majcherek, Maciej ;

Usnarska-Zubkiewicz, Lidia ;

Szukalski, Lukasz ;

Konska, Agnieszka ;

Zaucha, Jan M. ;

Walewski, Jan ;

Mikulski, Damian ;

Czabak, Olga ;

Robak, Tadeusz ;

Kruk-Kwapisz, Dorota ;

Lahoud, Oscar Boutros ;

Zonder, Jeffrey A. ;

Griffith, Kent ;

Stefka, Andrew T. ;

Jiang, Ken ;

Cooperrider, Jennifer H. ;

Derman, Ben A. ;

Jakubowiak, Andrzej J. .

BLOOD, 2023, 142

[39] Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial [J].

Weisel, Katja ;

Besemer, Britta ;

Haenel, Mathias ;

Lutz, Raphael ;

Mann, Christoph ;

Munder, Markus ;

Goerner, Martin ;

Reinhardt, Hans Christian ;

Nogai, Axel ;

Ko, Yon-Dschun ;

De Wit, Maike ;

Salwender, Hans ;

Scheid, Christoph ;

Graeven, Ullrich ;

Peceny, Rudolf ;

Staib, Peter ;

Dieing, Annette ;

Jauch, Anna ;

Zago, Manola ;

Benner, Axel ;

Tichy, Diana ;

Bokemeyer, Carsten ;

Goldschmidt, Hartmut ;

Leypoldt, Lisa B. .

BLOOD, 2022, 140 :1836-1838

[40] Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM). [J].

Derman, Benjamin Avi ;

Zonder, Jeffrey A. ;

Kansagra, Ankit J. ;

Grinblatt, David L. ;

Narula, Sunil ;

Rayani, Shayan ;

Stefka, Andrew T. ;

Jiang, Ken ;

Major, Sarah ;

Wolfe, Brittany ;

Whelan, Megan ;

Libao, Bernadette ;

McIver, Amanda ;

Andreatos, Evangelia ;

Juergens, Daniel ;

Alcantar, Luis ;

Karrison, Theodore ;

Bishop, Michael Russell ;

Jasielec, Jagoda ;

Jakubowiak, Andrzej J. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →